ELIZABETH L. ALTENHEIN, MD

PROVIDENCE, RI

Research Active
Surgery NPI registered 21+ years 1 publication 1997 – 1997 NPI: 1689670044
Surgery
Tomography, X-Ray ComputedPancreatic NeoplasmsCombined Modality TherapyStomach NeoplasmsRemission InductionNeutropeniaPaclitaxelAntineoplastic Agents, PhytogenicRadiation-Sensitizing Agents

Practice Location

100 HIGHLAND AVE
PROVIDENCE, RI 02906-2740

Phone: (401) 553-8360

What does ELIZABETH ALTENHEIN research?

Dr. Altenhein studies the treatment approaches for patients suffering from locally advanced pancreatic and gastric cancers, which are types of cancer that have spread significantly within the abdomen. Her research focuses on how combining the chemotherapy drug paclitaxel with radiation therapy can improve the effectiveness of treatment. By examining patient responses to these treatment combinations, she aims to find better ways to help manage these aggressive cancers.

Key findings

  • In her 1997 study, 48% of the 23 patients experienced improvements in their cancer after receiving a combination of paclitaxel and radiation therapy.
  • Most patients tolerated the treatments well, although some experienced side effects like abdominal pain and nausea, particularly at higher dosages.
  • This research opens avenues for more effective treatment options for advanced pancreatic and gastric cancer patients.

Frequently asked questions

Does Dr. Altenhein study pancreatic cancer?
Yes, Dr. Altenhein conducts research specifically on pancreatic cancer, focusing on treatment methods for advanced cases.
What treatments has Dr. Altenhein researched?
She has researched the effectiveness of combining the chemotherapy drug paclitaxel with radiation therapy for advanced pancreatic and gastric cancers.
Is Dr. Altenhein's work relevant to patients with gastric cancer?
Yes, her research directly addresses treatment options for patients with advanced gastric cancer in addition to pancreatic cancer.

Publications in plain English

Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study.

1997

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Safran H, King TP, Choy H, Hesketh PJ, Wolf B +9 more

Plain English
This study looked at how well the cancer drug paclitaxel works alongside radiation therapy for patients with advanced pancreatic and gastric cancers. They found that of the 23 patients whose cancer could be measured, 11 showed improvements, making the success rate 48%. The treatments were generally well tolerated, with some patients experiencing side effects like abdominal pain and nausea, especially at higher doses. Who this helps: This research benefits patients with locally advanced pancreatic and gastric cancer by exploring more effective treatment options.

PubMed

Frequent Co-Authors

H Safran T P King H Choy P J Hesketh B Wolf W Sikov A Rosmarin W Akerley K Radie-Keane G Cicchetti

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.